Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
60 Degrees Pharmaceuticals, Inc. (SXTP)
Company Research
Source: GlobeNewswire
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humansThe study will be the world’s first clinical trial to evaluate tafenoquine in human babesiosis patientsEnrollment will begin after a site initiation visit in Boston on June 13, 2024Agreements are being negotiated with two other prominent university hospitals to expand recruitment in the Northeast U.S. where the incidence of babesiosis has been increasing; babesiosis, a tick-borne and potentially life-threatening illness, is an orphan diseaseCase studies in the medical literature suggest that tafenoquine may be a promising alternative for the treatment of some patients hospitalized with relapsing babesiosis WASHINGTON, May 30, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medic
Show less
Read more
Impact Snapshot
Event Time:
SXTP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SXTP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SXTP alerts
High impacting 60 Degrees Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SXTP
News
- 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis [Yahoo! Finance]Yahoo! Finance
- 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute BabesiosisGlobeNewswire
- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind [Yahoo! Finance]Yahoo! Finance
- 60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study [Yahoo! Finance]Yahoo! Finance
SXTP
Sec Filings
- 6/12/24 - Form 8-K
- 5/30/24 - Form DEF
- 5/21/24 - Form 4
- SXTP's page on the SEC website